[On the role of psychological disorders in the development of the syndrome of pain dysfunction of the temporomandibular joint]. / O roli psikhologicheskikh faktorov v razvitii sindroma bolevoi disfunktsii visochno-nizhnechelyustnogo sustava.

There are significant disagreements related to the understanding of the etiopathogenesis of the syndrome of pain dysfunction of the temporomandibular joint. This review article examines the role of patient's psychological status as a significant factor influencing the occurrence and complications of this pathology, as evidenced by an increase in stress, anxiety, and depression in patients with the dysfunction. The need for a multidisciplinary and individual approach to the diagnosis and treatment is also discussed, which can significantly alleviate the severity of the disease, reduce complications, and shorten the rehabilitation time.

[Cariprazine in schizophrenia with predominantly negative symptoms: early effects of therapy (observational study)]. / Kariprazin v terapii shizofrenii s preobladaniem negativnykh simptomov: initsial'nye effekty lecheniya (observatsionnoe issledovanie).

BACKGROUND: Currently available antipsychotics have limited efficacy in the treatment of negative symptoms in schizophrenia and new drugs with wider spectrums of clinical efficacy are very desirable. Cariprazine is a newer antipsychotic acting as dopamine D3- and in lesser extent D2-receptor partial agonist found to be effective in the treatment of negative symptoms in schizophrenia. OBJECTIVES: To evaluate cariprazine early effects at the first stage of therapy of schizophrenia patients with predominantly negative symptoms. DESIGN AND PATIENTS: Open-lable observational assessment of 60 adult schizophrenia patients (F20 on ICD-10, 49% males) with predominantly negative symptoms (PANSS-FSNS ≥15, PANSS-FSPS <19) treated by cariprazine (starting daily dose 1.5 mg followed by upward titration by 1.5 mg weekly up to 6 mg if needed) were assessed with PANSS, CAINS, CDSS and SAS scales at baseline and on week 1, 2, and 4. Efficacy criteria were. RESULTS: Most patients (75%) improved during 28 days of cariprazine treatment. Negative symptoms mean total scores on PANSS-NS and CAINS significantly (p<0.05) reduced by 4.3 and 4.9 respectively at the end of assessment (day 28). Cariprazine tolerability was good, only 4 patients discontinued because of TEAEs (akathisia, insomnia). CONCLUSIONS: The study results preliminary suggest initial effect of cariprazine on negative symptoms at least in some schizophrenia patients with predominantly negative symptoms starting from 1-2 weeks of treatment and available for observation and assessment and could be useful for determination of early clinical predictors for efficacy. Considering limitations of observational open-lable design with no control groups these data need to be confirmed.